The incidence of dyslipidemia (hypertriglyceridemia and hypercholesterolemia) in patients treated with the new generation of antipsychotic drugs compared to conventional therapy;Incidenca dislipidemije kod pacijenata liječenih novom generacijom antipsihotika u odnosu na pacijente koji su tretirani klasičnim antipsihoticima

Medicinski Glasnik

Volumn 11, Issue 2, 2014, Pages 350-355

  Sadibašić, Belma ^a   Macić Džanković, Amra ^b   Šabić, Azra ^b   Torlak, Bajro ^a   Lastrić, Gordana ^a   Ćustović, Amir ^a  

^a Zenica Cantonal Hospital   (Bosnia and Herzegovina)

^b General Hospital Sarajevo   (Bosnia and Herzegovina)

Author keywords

Antipsychotics of new generation; Disorder; Lipids

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PROMAZINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; RETROSPECTIVE STUDY; BOSNIA AND HERZEGOVINA; CHEMICALLY INDUCED; DYSLIPIDEMIAS; MIDDLE AGED;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BOSNIA-HERZEGOVINA; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84948142947     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tonstand S, Hjermann I. A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women. J Cardiovasc Risk 2003; 10: 129-35.
2. Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008; 101: 287-94.
3. Atmaca M. Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
4. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006; 16: 149-55.
5. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res 2009; 107: 115-21.
6. Cormac I, Ferriter M, Bening R, Saul C. Physical health and health risk factors in a population of longstay psychiatric patients. Psychiatr Bull 2005; 29: 18-20.
7. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial prospective data from phase 1. Schizophr Res 2008; 101: 273-86.
8. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119: 171-9.
9. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001; 322: 443-4.
10. Reist C, Mintz J, Albers LJ, Jamas MM, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 46-51.
11. Tandon R, Jibson MD. Efficasy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28(Suppl 1): 9-26.
12. Uzun S, Kozumplik O, Mimica N, Folnegovic Šmalc V. Nuspojave psihofarmaka. Zagreb: Medicinska naklada, 2005.
13. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs inatients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
14. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB. Minimising metabolic and cardiovascular risk factors in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21: 357-73.
15. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155: 230-3.
16. Ginsberg HN. Treatment for patients with metabolic syndrome. Am J Cardiol 2003; 91: 29-39.
17. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, Ujkaj M, Pastorelli R, Berardi D. Metabolic risk factor profile associated with use of second generation antipsychotics. A cross sectional study in a community mental health centre. BMC Psychiatry 2006; 6: 11-8.
18. Lewis DA. Atypical antipsychotic medications and the treatment of schizophrenia. Am J Psychiatry 2002; 159: 177-9.
19. De Hert MA, van Winkel R, van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Shizophr Res 2006; 83: 87-93.
20. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl): 1-56.
21. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsbi R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora j, Jones PB. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidemia. J Psychopharmacol 2007; 21: 4: 357-73.
22. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132-7.
23. Chui Chih-Chiang, Chun-Hsin Chen, Bo-Yu Chen, Shu-Han Yu, Mong-Liang Lu. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 866-70.
24. Medved V, Rojnic Kuzman M, Jovanovic N, Grubisin J, Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J Psychopharmacol 2008; 23: 915-22.
25. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.